Two Separate Clusters of SARS-CoV-2 Delta Variant Infections in a Group of 41 Students Travelling from India: An Illustration of the Need for Rigorous Testing and Quarantine.
COVID-19
Delta variant
SARS-CoV-2
SARS-CoV-2 variants
communicable disease control
quarantine
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
01
05
2022
revised:
16
05
2022
accepted:
26
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
We report two clusters of SARS-CoV-2 B.1.617.2 (Delta variant) infections in a group of 41 Indian nursing students who travelled from New Delhi, India, to Belgium via Paris, France. All students tested negative before departure and had a second negative antigen test upon arrival in Paris. Upon arrival in Belgium, the students were quarantined in eight different houses. Four houses remained COVID-free during the 24 days of follow-up, while all 27 residents of the other four houses developed an infection during quarantine, including the four residents who were fully vaccinated and the two residents who were partially vaccinated. Genome sequencing revealed two distinct clusters affecting one and three houses, respectively. In this group of students, vaccination status did not seem to prevent infection nor decrease the viral load. No severe symptoms were reported. Extensive contact tracing and 3 months of nationwide genomic surveillance confirmed that these outbreaks were successfully contained and did not contribute to secondary community transmission in Belgium. These clusters highlight the importance of repeated testing and quarantine measures among travelers coming from countries experiencing a surge of infections, as all infections were detected 6 days or more after arrival.
Identifiants
pubmed: 35746671
pii: v14061198
doi: 10.3390/v14061198
pmc: PMC9229483
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Nat Commun. 2022 Jan 24;13(1):460
pubmed: 35075154
PLoS Biol. 2006 May;4(5):e88
pubmed: 16683862
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
BMJ Open. 2021 Jul 16;11(7):e050473
pubmed: 34272225
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
Syst Biol. 2019 Nov 1;68(6):1052-1061
pubmed: 31034053
PLoS Comput Biol. 2009 Sep;5(9):e1000520
pubmed: 19779555
Cochrane Database Syst Rev. 2021 Mar 25;3:CD013717
pubmed: 33763851
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Lancet Public Health. 2021 Sep;6(9):e674-e682
pubmed: 34388389
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Nat Med. 2021 Jul;27(7):1131-1133
pubmed: 34045737
Curr Ther Res Clin Exp. 2020;93:100607
pubmed: 33071295
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Mol Evol. 1994 Sep;39(3):306-14
pubmed: 7932792
BMJ. 2021 Jun 4;373:n1445
pubmed: 34088699
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
J Mol Evol. 1984;20(1):86-93
pubmed: 6429346
Epidemiol Infect. 2020 Jun 19;148:e117
pubmed: 32594928
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Lancet Infect Dis. 2021 Jul;21(7):929-938
pubmed: 33765417
Int J Infect Dis. 2021 Mar;104:708-710
pubmed: 33548553